A Phase 2 interventional study of Panitumumab and Bevacizumab in Cancer, Colon Cancer and Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 17th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 60 in phase 2, and was the 15th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
AbbVie · Sites in United States, Australia, Austria and 12 more countries
Ages 18+
R-Pharm · Sites in Russia
Ages 18+
UNICANCER · Sites in France
Ages 18+
Amgen · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+
By country, each count listing its studies:
Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 68 · Phase 3 15 · Phase 4 1
First in 2000; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 266 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 70 across the 88 interventional studies. Of the 67 that completed or were terminated, 30 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 90 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
40 studies in Colorectal Neoplasms by Amgen: 2 open now, 2 under way, 1 of them phase 3. Of 38 finished, 24 (63%) have results posted.
Among the 40 studies in Colorectal Neoplasms by Amgen, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2006, is one of 16 in phase 2, and was the 14th registered.
Amgen’s Colorectal Neoplasms studies by the year they started, since 2002.
3 of the studies testing panitumumab in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03087071M.D. Anderson Cancer CenterPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | 2027-01-31 |
| NCT05845450Gruppo Oncologico del Nord-OvestPre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | 2027-05 |
| NCT07318389M.D. Anderson Cancer CenterASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 90 studies testing panitumumab in Colorectal Neoplasms, from their registry updates:
Among Amgen’s 40 in Colorectal Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care).
This phase 2, multicenter, open-label, randomized, two-arm study was designed to estimate the treatment effect of panitumumab in combination with FOLFIRI compared to bevacizumab in combination with FOLFIRI in subjects with metastatic colorectal cancer (mCRC) who had failed first-line therapy with at least 4 doses of oxaliplatin-based chemotherapy and bevacizumab. After data became available demonstrating that the treatment effect of antiepidermal growth factor receptor (EGFR) agents was limited to patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) mCRC, the study was amended to enroll only subjects with wild-type KRAS tumors. Eligible subjects were randomized in a 1:1 ratio to receive panitumumab 6 mg/kg plus FOLFIRI once every 2 weeks (Q2W) or bevacizumab 5 mg/kg or 10 mg/kg plus FOLFIRI Q2W. Randomization was stratified by the reason for first-line treatment failure (progression vs toxicity) and by intended bevacizumab dose (5 mg/kg vs 10 mg/kg). The intended bevacizumab doses were ascertained from sites at the time of site initiation. Subjects were treated with all or any components of second-line treatment until the occurrence of unacceptable adverse events, disease progression, death, loss to follow up, or study withdrawal by the subject, investigator, or sponsor. Tumor response was evaluated by blinded central radiology review per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 and by the investigator using either modified RECIST version 1.0 or clinical assessment. After subjects permanently discontinued all components of second-line treatment, they were to undergo a safety follow-up assessment 30 (± 7) days after the last dose. Subjects ending second-line treatment before disease progression were followed for PFS (radiographic disease assessment) every 12 weeks (± 14 days) from the safety follow-up visit until disease progression, initiation of a new therapy for mCRC, or until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors. Subjects were also followed for survival every 12 weeks (± 14 days) from the safety follow-up assessment until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
This study's enrollment of 266 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Medications
General:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOLFIRI + Panitumumab
Drug: Panitumumab · Drug: Leucovorin · Drug: Irinotecan · Drug: 5-Fluorouracil
FOLFIRI + Bevacizumab
Drug: Bevacizumab · Drug: Leucovorin · Drug: Irinotecan · Drug: 5-Fluorouracil
6mg/kg IV
Either 5mg/kg OR 10mg/kg IV
400mg/m\^2 IV (in the vein)
180mg/m\^2 IV (in the vein)
400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects
Progression-free Survival (PFS)
Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later).
Time frame: From randomization up to 65 months.
Overall Survival
Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date.
Time frame: From randomization up to 65 months.
Objective Response Rate
Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment.
Time frame: From randomization up to 65 months.
Time to Response
Time to response is defined as time from the date of randomization to the date of first confirmed objective response
Time frame: From randomization up to 65 months.
Time to Progression
Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment).
Time frame: From randomization up to 65 months.
Disease Control
Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy.
Time frame: From randomization up to 65 months.
Duration of Response
Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment).
Time frame: From randomization up to 65 months.
| Milestone | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Started | 133 | 131 |
| Completed | 109 | 108 |
| Not completed | 24 | 23 |
| Withdrew: Reimbursement | 1 | 0 |
| Withdrew: Administrative decision | 3 | 3 |
| Withdrew: Withdrawal by subject | 16 | 15 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: On-going | 1 | 1 |
| Withdrew: Ineligibility determined | 1 | 0 |
Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later).
| months | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 7.7 (5.7 to 11.8) | 9.2 (7.8 to 10.6) |
| Mutant KRAS (n=36,32) | 3.7 (2.7 to 5.5) | 6.4 (3.5 to 17.1) |
Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date.
| months | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 18.0 (13.5 to 21.7) | 21.4 (16.5 to 24.6) |
| Mutant KRAS (n=36,32) | 8.7 (6.1 to 14.5) | 13.5 (9.1 to 14.3) |
Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment.
| % of patients | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 32.18 (22.56 to 43.06) | 19.28 (11.44 to 29.41) |
| Mutant KRAS (n=36,32) | 11.76 (3.30 to 27.45) | 3.33 (0.08 to 17.22) |
Time to response is defined as time from the date of randomization to the date of first confirmed objective response
| months | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 2.1 ± 2.2 | 3.7 ± 1.2 |
| Mutant KRAS (n=36,32) | 2.2 ± 0.2 | 1.8 ± NA |
Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment).
| months | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS | 11.1 (7.5 to 13.2) | 9.4 (8.2 to 11.9) |
| Mutant KRAS | 4.5 (3.0 to 12.0) | 7.4 (5.7 to 19.2) |
Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy.
| % of participants | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 72.41 (61.79 to 81.46) | 79.52 (69.24 to 87.59) |
| Mutant KRAS (n=36,32) | 52.94 (35.13 to 70.22) | 66.67 (47.19 to 82.71) |
Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment).
| months | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| Wild-type KRAS (n=91,91) | 12.7 (7.9 to 19.1) | 8.9 (6.5 to 13.6) |
| Mutant KRAS (n=36,32) | 10.2 (9.8 to 13.5) | 15.2 (NA to NA) |
Collected over The median reporting period was since randomization date to 65 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab Plus FOLFIRI | — | 61/133 (45.9%) | 133/133 (100%) |
| Bevacizumab Plus FOLFIRI | — | 39/131 (29.8%) | 129/131 (98.5%) |
| Event | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/133 | 4/131 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 8/133 | 1/131 |
| DehydrationMetabolism and nutrition disorders | 7/133 | 6/131 |
| VomitingGastrointestinal disorders | 5/133 | 3/131 |
| Abdominal painGastrointestinal disorders | 4/133 | 4/131 |
| Small intestinal obstructionGastrointestinal disorders | 4/133 | 3/131 |
| NeutropeniaBlood and lymphatic system disorders | 2/133 | 3/131 |
| NauseaGastrointestinal disorders | 2/133 | 3/131 |
| Urinary tract infectionInfections and infestations | 3/133 | 3/131 |
| SepsisInfections and infestations | 3/133 | 2/131 |
| Event | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 93/133 | 87/131 |
| NauseaGastrointestinal disorders | 69/133 | 88/131 |
| FatigueGeneral disorders | 76/133 | 80/131 |
| RashSkin and subcutaneous tissue disorders | 80/133 | 9/131 |
| NeutropeniaBlood and lymphatic system disorders | 44/133 | 53/131 |
| VomitingGastrointestinal disorders | 47/133 | 47/131 |
| HypomagnesaemiaMetabolism and nutrition disorders | 47/133 | 14/131 |
| ConstipationGastrointestinal disorders | 43/133 | 34/131 |
| HypokalaemiaMetabolism and nutrition disorders | 42/133 | 23/131 |
| Decreased appetiteMetabolism and nutrition disorders | 38/133 | 41/131 |
| Age, Continuous(years) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| Mean | 59.9 ± 11.6 | 59.1 ± 9.9 | 59.5 ± 10.8 |
| Sex: Female, Male(Participants) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| Female | 46 | 46 | 92 |
| Male | 87 | 85 | 172 |
| Race/Ethnicity, Customized(Participants) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| White or Caucasian | 102 | 95 | 197 |
| Black or African American | 21 | 18 | 39 |
| Hispanic or Latino | 5 | 9 | 14 |
| Asian | 4 | 8 | 12 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| 0 (Fully active) | 74 | 70 | 144 |
| 1 (Restricted in physically strenuous activity) | 58 | 61 | 119 |
| Missing | 1 | 0 | 1 |
| Primary tumor diagnosis(Participants) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| Colon | 102 | 91 | 193 |
| Rectum | 31 | 40 | 71 |
| Number of metastatic organs(Participants) | Panitumumab Plus FOLFIRI | Bevacizumab Plus FOLFIRI | Total |
|---|---|---|---|
| 1 | 49 | 61 | 110 |
| 2 | 39 | 42 | 81 |
| >=3 | 44 | 28 | 72 |
| Missing | 1 | 0 | 1 |
No study locations are listed for this record.
Ran from Nov 2006 to primary completion in May 2012, 66 months.
Results were first posted in Mar 2014, 1 year 10 months after primary completion. A results delay was requested in Jul 2010.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 66 months is above that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Panitumumab · Bevacizumab